These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35833245)

  • 21. Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients.
    Cheng X; Li YN; Fan YB; Zhao HH; Li L; Lu C; Zhu LH; Niu Q
    Clin Neurol Neurosurg; 2024 Sep; 244():108462. PubMed ID: 39047390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy.
    Schorling DC; Kölbel H; Hentschel A; Pechmann A; Meyer N; Wirth B; Rombo R; ; Sickmann A; Kirschner J; Schara-Schmidt U; Lochmüller H; Roos A
    Eur J Neurol; 2022 Jul; 29(7):2084-2096. PubMed ID: 35318785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF IL-8 Associated with Response to Gene Therapy in a Case Series of Spinal Muscular Atrophy.
    Verma S; Perry K; Razdan R; Howell JC; Dawson AL; Hu WT
    Neurotherapeutics; 2023 Jan; 20(1):245-253. PubMed ID: 36289175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.
    Li JY; Dai Y; Sun XH; Ren HT; Shen DC; Yang XZ; Liu MS; Cui LY
    Brain Behav; 2023 May; 13(5):e2997. PubMed ID: 37070132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3.
    Hiebeler M; Abicht A; Reilich P; Walter MC
    J Neuromuscul Dis; 2021; 8(4):537-542. PubMed ID: 33682724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NFL is a marker of treatment response in children with SMA treated with nusinersen.
    Olsson B; Alberg L; Cullen NC; Michael E; Wahlgren L; Kroksmark AK; Rostasy K; Blennow K; Zetterberg H; Tulinius M
    J Neurol; 2019 Sep; 266(9):2129-2136. PubMed ID: 31123861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
    Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
    J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Children and young adults with spinal muscular atrophy treated with nusinersen.
    Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
    Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
    Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
    J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF chitinase proteins in amyotrophic lateral sclerosis.
    Thompson AG; Gray E; Bampton A; Raciborska D; Talbot K; Turner MR
    J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1215-1220. PubMed ID: 31123140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment.
    Freigang M; Wurster CD; Hagenacker T; Stolte B; Weiler M; Kamm C; Schreiber-Katz O; Osmanovic A; Petri S; Kowski A; Meyer T; Koch JC; Cordts I; Deschauer M; Lingor P; Aust E; Petzold D; Ludolph AC; Falkenburger B; Hermann A; Günther R
    Ann Clin Transl Neurol; 2021 May; 8(5):1049-1063. PubMed ID: 33792208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma as a Nusinersen treatment response marker in childhood-onset SMA individuals from Serbia.
    Brkušanin M; Kosać A; Branković-Srećković V; Jovanović K; Perić S; Karanović J; Matijašević Joković S; Garai N; Pešović J; Nikolić D; Stević Z; Brajušković G; Milić-Rašić V; Savić-Pavićević D
    Front Neurol; 2024; 15():1394001. PubMed ID: 38756215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: A case report focusing on the neurofilament light chain in cerebrospinal fluid.
    Tozawa T; Kasai T; Tatebe H; Shiomi K; Nishio H; Tokuda T; Chiyonobu T
    Brain Dev; 2020 Mar; 42(3):311-314. PubMed ID: 31889567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
    Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
    Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression.
    Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS
    J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
    Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
    Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy.
    Panicucci C; Sahin E; Bartolucci M; Casalini S; Brolatti N; Pedemonte M; Baratto S; Pintus S; Principi E; D'Amico A; Pane M; Sframeli M; Messina S; Albamonte E; Sansone VA; Mercuri E; Bertini E; Sezerman U; Petretto A; Bruno C
    Cell Mol Life Sci; 2024 Sep; 81(1):393. PubMed ID: 39254732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.